Skip to main content
. 2020 Oct 6;8(1):e001537. doi: 10.1136/bmjdrc-2020-001537

Figure 4.

Figure 4

HR for developing diabetes in those who took at least some study metformin during DPPOS (n=652)*. HRs and their 95% CIs from a Cox Proportional Hazards model for time to diabetes measured from DPPOS baseline. All variables listed in the figure are covariates included in a multivariate model. Age, marital status, educational level, employment status, and income level were all measured at DPP baseline. The follow-up SF-36 and number of concomitant medications variables are averages during follow-up. Cumulative metformin adherence is calculated as the cumulative per cent of visits (up to and including each collection time point) at which a participant took 80% or more of their prescribed study metformin. *Includes only participants whose diagnosis of diabetes, or censoring, occurred on or after August 1, 2002 (the official start date of DPPOS) were included in this analysis. There was a total of 216 participants from this study who developed diabetes prior to the start of DPPOS. Depression scores, anxiety scores, and number of concomitant medications were included in the models as logged values, so estimates of OR for these covariates are expressed per 1-unit log increase. DPP, Diabetes Prevention Program; DPPOS, DPP Outcomes Study; SF-36, Short Form-36.